Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis
- PMID: 31825646
- PMCID: PMC7924656
- DOI: 10.1164/rccm.201906-1250OC
Income and Other Contributors to Poor Outcomes in U.S. Patients with Sarcoidosis
Abstract
Rationale: Socioeconomic factors are associated with worse disease severity at presentation in sarcoidosis, but the relative importance of socioeconomic variables on morbidity and disease burden has not been fully elucidated.Objectives: To determine the association between income and sarcoidosis outcomes after controlling for socioeconomic and disease-related factors.Methods: Using the Sarcoidosis Advanced Registry for Cures database, we analyzed data from 2,318 patients with sarcoidosis in the United States to determine the effect of income and other variables on outcomes. We divided comorbidities arising after diagnosis into those likely related to steroid use and those likely related to sarcoidosis. We assessed the development of health-related, functional, and socioeconomic outcomes following the diagnosis of sarcoidosis.Measurements and Main Results: In multivariate analysis, low-income patients had significantly higher rates of new sarcoidosis-related comorbidities (<$35,000, odds ratio [OR], 2.4 [1.7-3.3]; $35,000-84,999, OR, 1.4 [1.1-1.9]; and ≥$85,000 [reference (Ref)]) and new steroid-related comorbidities (<$35,000, OR, 1.3 [0.9-2.0]; $35,000-84,999, OR, 1.5 [1.1-2.1]; and ≥$85,000 [Ref]), had lower health-related quality of life as assessed by the Sarcoidosis Health Questionnaire (P < 0.001), and experienced more impact on family finances (<$35,000, OR, 7.9 [4.9-12.7]; $35,000-84,999, OR, 2.7 [1.9-3.9]; and ≥$85,000 [Ref]). The use of supplemental oxygen, need for assistive devices, and job loss were more common in lower income patients. Development of comorbidities after diagnosis of sarcoidosis occurred in 63% of patients and were strong independent predictors of poor outcomes. In random forest modeling, income was consistently a leading predictor of outcome.Conclusions: These results suggest the burden from sarcoidosis preferentially impacts the economically disadvantaged.
Keywords: comorbidity; healthcare disparities; sarcoidosis; socioeconomic factors.
Figures
Comment in
-
Sarcoidosis: An Ill-afforded Disease.Am J Respir Crit Care Med. 2020 Apr 15;201(8):890-891. doi: 10.1164/rccm.202001-0047ED. Am J Respir Crit Care Med. 2020. PMID: 31978312 Free PMC article. No abstract available.
References
-
- Grunewald J, Grutters J, Arkema E, Saketkoo L, Moller D, Muller-Quernheim J. Sarcoidosis. Nat Rev Dis Primer. 2019;5 - PubMed
-
- Wells AU. Sarcoidosis: a benign disease or a culture of neglect? Respir Med. 2018;144S:S1–S2. - PubMed
-
- Martusewicz-Boros MM, Boros PW, Wiatr E, Roszkowski-Śliż K. What comorbidities accompany sarcoidosis? A large cohort (n=1779) patients analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:115–120. - PubMed
-
- Kostorz S, Jastrzębski D, Sikora M, Zebrowska A, Margas A, Stepanik D, et al. Predominance of comorbidities in the detriment of daily activity in sarcoidosis patients. Adv Exp Med Biol. 2018;1040:7–12. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
